TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, today announced that interim data from the marginal zone lymphoma (MZL) cohort of the UNITY-NHL Phase 2b pivotal trial to be presented at the upcoming American Association for Cancer Research (AACR) annual meeting has an updated embargo date and time of Monday, April 1, 2019 at 8:30am ET. At that time, the abstract will be available via the AACR meeting website at http://www.aacr.org, and the data which will be presented during an oral session later that day (details below) will be available on the Company’s website at http://www.tgtherapeutics.com/publications.cfm.
The Company will also host a conference call with Dr. Nathan Fowler of the MD Anderson Cancer Center and Study Chair of the UNITY-NHL MZL cohort at 12:00pm(noon) ET on Monday April 1, 2019 to review the UNITY-NHL MZL interim data.
The Company will host a conference call on Monday April 1, 2019, 12:00pm (noon) ET. Michael S. Weiss, Chief Executive Officer of TG Therapeutics, will host the call, and Dr. Nathan Fowler, Associate Professor of Medicine and Director of Clinical Research in the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center in Houston, will review the UNITY-NHL interim MZL data.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics AACR Update Call.
A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.